-
Why metal prices are soaring to record highs
-
Stocks tepid in thin pre-Christmas trade
-
UN experts slam US blockade on Venezuela
-
Bethlehem celebrates first festive Christmas since Gaza war
-
Set-piece weakness costing Liverpool dear, says Slot
-
Two police killed in explosion in Moscow
-
EU 'strongly condemns' US sanctions against five Europeans
-
Arsenal's Kepa Arrizabalaga eager for more League Cup heroics against Che;sea
-
Thailand-Cambodia border talks proceed after venue row
-
Kosovo, Serbia 'need to normalise' relations: Kosovo PM to AFP
-
Newcastle boss Howe takes no comfort from recent Man Utd record
-
Frank warns squad to be 'grown-up' as Spurs players get Christmas Day off
-
Rome pushes Meta to allow other AIs on WhatsApp
-
Black box recovered from Libyan general's crashed plane
-
Festive lights, security tight for Christmas in Damascus
-
Zelensky reveals US-Ukraine plan to end Russian war, key questions remain
-
El Salvador defends mega-prison key to Trump deportations
-
Stranger Things set for final bow: five things to know
-
Grief, trauma weigh on survivors of catastrophic Hong Kong fire
-
Asian markets mixed after US growth data fuels Wall St record
-
Stokes says England player welfare his main priority
-
Australia's Lyon determined to bounce back after surgery
-
Stokes says England players' welfare his main priority
-
North Korean POWs in Ukraine seeking 'new life' in South
-
Japanese golf star 'Jumbo' Ozaki dies aged 78
-
Johnson, Castle shine as Spurs rout Thunder
-
Thai border clashes hit tourism at Cambodia's Angkor temples
-
From predator to plate: Japan bear crisis sparks culinary craze
-
Asian markets mostly up after US growth fuels Wall St record
-
'Happy milestone': Pakistan's historic brewery cheers export licence
-
Chevron: the only foreign oil company left in Venezuela
-
US denies visas to EU ex-commissioner, four others over tech rules
-
Dynamite Blockchain Delivers Record Q3 2025
-
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
-
SMX's Integrated Value Proposition: One System, Many Markets, Compounding Leverage
-
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
-
Alta Copper Announces Filing and Mailing of Meeting Materials for the Special Meeting of Shareholders and Optionholders to be Held on January 26, 2026
-
Pantheon Resources PLC Announces TR-1: Notification of Major Holdings
-
Bridgeline Expands Footprint with Closeout Retailer Choosing HawkSearch for Its On-Site Search Experience and Personalization
-
Koepka leaves LIV Golf: official
-
US slams China policies on chips but will delay tariffs to 2027
-
Arsenal reach League Cup semis with shoot-out win over Palace
-
Contenders Senegal, Nigeria start Cup of Nations campaigns with wins
-
Tunisia ease past Uganda to win Cup of Nations opener
-
S&P 500 surges to record after strong US economic report
-
UK police say no action against Bob Vylan duo over Israel army chant
-
Libya's top military chief killed in plane crash in Turkey
-
Venezuela passes law to jail backers of US oil blockade
-
French parliament passes emergency budget extension
RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
L.Davis--AMWN